American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respira...
American Oriental Bioengineering reported revenue of $145.10 million for fiscal year 2012, down 31.8% from fiscal year 2011, and net income of -$59.71 million. In Q3 2013 (the quarter ended September 30, 2013) revenue was $17.94 million, down 39.2% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2012.
No profile data available.